ReviewBiochemistry and biophysics reports2025
The impact of the recent HIV non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors-based regimens on metabolic health outcomes: A narrative review.
Review in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of human immunodeficiency virus (HIV) has led to a significant rise in the chronic use of antiretroviral (ARV) drugs, both for HIV management and pre-exposure prophylaxis (PrEP), to meet the set Joint United Nations Programme on HIV/AIDS (UNAIDS) 95-95-95 targets. Although antiretroviral therapy (ART) has remarkably increased the life expectancy of people living with HIV (PLHIV), it has also been associated with metabolic complications, particularly in glucose and lipid metabolism. Notably, the development of type two diabetes mellitus (T2DM), accounting for 90-95 % of diabetes cases, often stems from an asymptomatic prediabetic state, frequently left undiagnosed. In this narrative review, we address the limited understanding of how prediabetic individuals respond to chronic exposure to antiretroviral therapy. The scope of this review focuses on selected markers of pancreatic metabolic dysfunction, the interplay between modern ARV therapies and prediabetes will be examined. In efforts to enhance and further expand the understanding of potential risks and outcomes of ARVs on metabolically compromised individuals. Through a comprehensive synthesis of existing literature and novel findings from the animal model,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.